Stimulate hair growth with FOL005 gel

Our product FOL005 is a unique and patented peptide based product that has been tested on more than 300 persons with hairloss with potent effect on hair growth stimulation after only 4 months, once daily, with no side effects.

About

Follicum AB is a biotech company in the Coegin Pharma Group. We are developing dermacosmetic products based on the FOL005 peptide which can stimulate hair growth for both men and women suffering from hair loss. FOL005 is a peptide based product that has shown, in several studies, to be safe and tolerable. Our objective is to launch FOL005 globally in collaboration with leading commercial partners in the dermacosmetics business area, with the US as the first market, in 2025.

Background

The market for treatment of androgenetic alopecia (hair loss) is substantial. In the US alone 60 million men and 35 million women are suffering from hair loss whereas only 2,7 million men and 2 million women are being treated. The current market for medical treatments is valued at more than 8 billion USD globally (https://www.grandviewresearch.com/industry-analysis/alopecia-market).

Finasteride and minoxidil are the dominant medical treatments, which have limited effect and only up to 40% of patients respond to treatment. In the last 30 years no new medical treatment has been introduced and the pipeline is based mainly on reformulation of these existing therapies.